TLSA: Intranasal Foralumab in COVID-19 msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
By John Vandermosten, CFA NASDAQ:TLSA | LSE:TILS READ THE FULL TLSA RESEARCH REPORT On May 25, 2021, Tiziana Life Sciences PLC (NASDAQ:TLSA ) (LSE:TILS) announced that it had initiated a trial through the Individual Patient Expanded Access Program (EAP) of foralumab in a Secondary Progressive Multiple Sclerosis (SPMS) patient. This follows a previous release in late March that first introduced the effort that was cleared under the EAP. The first.
First SPMS Patient Dosed With Nasal Spray Antibody Foralumab multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.
(0)
How great is this? As someone who gave himself an injection in his thigh for many years and received IV infusions for many more, an MS antibody treatment sprayed into the nose is wonderful news. T
his approval only applies to one patient, however. A Phase 1 clinical trial is underway, and a Phase 2 is expected to begin later this year. I hope this nasal spray, which initially was intended to be an oral medication, proves to be safe and effective.
For a first time, an immune-modulating antibody will be given via nasal administration to treat a person with secondary progressive multiple sclerosis (SPMS).
SPMS Patient First To Be Treated With Antibody Given via Nasal Spray multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.